- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02077036
Narcolepsy - New Potential Treatment
February 28, 2014 updated by: Lars Hyllienmark, Karolinska University Hospital
The overall aim of the study is to investigate the effect of a new, non-pharmacological method that may alleviate the symptoms of narcolepsy and thereby lead to a reduction in the use of medications with potentially serious side effects in patients with this disease.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden
- Recruiting
- Karolinska University Hospital
-
Principal Investigator:
- Lars Hyllienmark, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 60 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Diagnosed with narcolepsy (diagnose code G47.4)
- 16 - 60 years of age
- MSLT has shown hypersomnia (sleeping latency < 8 min) & 1 episode REM
- HLA-type associated with increased occurrence of narcolepsy
Exclusion Criteria:
- Reduced cognitive function
- Other relevant organ disease (that could affect the study results or put the patient at risk)
- Ongoing bacterial infection in the nose
- Comorbidity that can increase the risk of bleeding
- Has received treatment with an implantable stimulator or other implantable product in the head and / or in the neck
- Known pronounced septal deviation
- Known allergy to polyvinylchloride or medicinal liquid paraffin
- Women not using adequate contraceptives
- Participated in a clinical investigational drug trial within the previous 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Active medical device
|
|
|
PLACEBO_COMPARATOR: Inactive medical device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in scale Epworth Sleep Scale (ESS)
Time Frame: 15-21 days
|
Change in ESS scale between baseline before treatment and at 15-21 days after treatment.
|
15-21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in multiple sleep latency test (MSLT)
Time Frame: 14 days
|
Change in MSLT (mean sleep latency, number of sleep onset rapid eye movement (SOREM), and mean SOREM latency) between registration at baseline and 14 days after treatment.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Primary Completion (ANTICIPATED)
December 1, 2014
Study Registration Dates
First Submitted
February 11, 2014
First Submitted That Met QC Criteria
February 28, 2014
First Posted (ESTIMATE)
March 4, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
March 4, 2014
Last Update Submitted That Met QC Criteria
February 28, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- nervus11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityCompletedNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
TakedaRecruitingNarcolepsy With Cataplexy | Narcolepsy Type 1 (NT1)United States, France, Germany, Netherlands, Switzerland
-
Vertex Pharmaceuticals IncorporatedNot yet recruitingNarcolepsy Type 1 (NT1)
-
University of UtahNot yet recruitingNightmare | Narcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Nightmare Disorder With Associated Other Sleep DisorderUnited States
-
Centessa Pharmaceuticals (UK) LimitedRecruitingNarcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Centessa Pharmaceuticals (UK) LimitedRecruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States, Spain, Canada, France, Italy
-
Boston Children's HospitalAmerican Academy of Sleep MedicineCompletedIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
Clinical Trials on Kinetic Oscillation Stimulation Device
-
Karolinska University HospitalUnknownChronic Fatigue Syndrome | Myalgic EncephalomyelitisSweden
-
Chordate MedicalTerminatedChronic MigraineUnited Kingdom, Germany, Israel, Italy
-
Chordate MedicalTerminatedChronic MigraineUnited Kingdom
-
Christoph NissenCompletedInsomnia | SleepSwitzerland
-
DreemUniversity of Paris 5 - Rene DescartesCompleted
-
Universidade Luterana do BrasilCompletedOsteoarthritis, Knee | Exercise Addiction | Self Stimulation
-
October 6 UniversityCompleted
-
Andrew KrystalRecruitingBipolar II Disorder, Most Recent Episode Major Depressive | Bipolar II DisorderUnited States
-
Neurolief Ltd.Completed
-
Neurolief Ltd.Terminated